D-0666-2017 Class II Terminated
FDA drug recall D-0666-2017 was initiated by Medisca, Inc. on Apr 3, 2017 and is designated Class II. Reason for recall: cGMP Deviations; manufacturer initiated recall of API product after deficiencies noted during a recent FDA inspection The recall status is terminated (terminated Jun 18, 2019).
Recall details
- Product Type
- Drugs
- Report Date
- Apr 19, 2017
- Initiation Date
- Apr 3, 2017
- Termination Date
- Jun 18, 2019
- Voluntary/Mandated
- Voluntary: Firm initiated
Product description
ESTRADIOL, USP Bulk (Hemihydrate), in a) 25 g (NDC 38779-2261-04) and b) 100 g (NDC 38779-2261-05) bottles, Packed by MEDISCA INC. PLATTSBURGH, NY Product Code 2261
Reason for recall
cGMP Deviations; manufacturer initiated recall of API product after deficiencies noted during a recent FDA inspection
Distribution pattern
Nationwide, Australia, Bahamas, Italy, Singapore, Thailand, United Kingdom
Code information
a) 129669/C, 129669/F, 129669/H, 129669/J, 130941/B 130941/D, 130941/F, 136108/B, 139091/B; b) 129669/B, 129669/E, 130941/A, 130941/C, 130941/E,130941/G, 136108/A,
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0666-2017
- openFDA file date
- Nov 16, 2026
- Loaded by RegDataLab
- Nov 17, 2026